Buscar en
Annals of Hepatology
Toda la web
Inicio Annals of Hepatology Perspectives on NASH Histology: Cellular Ballooning
Journal Information
Vol. 16. Issue 2.
Pages 182-184 (March - April 2017)
Share
Share
Download PDF
More article options
Vol. 16. Issue 2.
Pages 182-184 (March - April 2017)
Open Access
Perspectives on NASH Histology: Cellular Ballooning
Visits
3899
Stephen Caldwell
,
Corresponding author
shc5c@virginia.edu

Correspondence and reprint request:
, Carolin Lackner**
* The University of Virginia, Division of GI/Hepatology, Charlottesville, Virginia, USA
1 The University of Graz, Department of Pathology, Graz, Austria
This item has received

Under a Creative Commons license
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Abstract

Interpretation of liver biopsy in NAFLD can be challenging to distinguish histological NASH from non-NASH fatty liver – a broad dichotomy which carries significant prognostic and therapeutic implications and underlies the utility of many non-invasive tests. There is usually a reasonable degree of inter-observer agreement for some key parameters like steatosis, inflammation and fibrosis staging. However, the assessment of cellular ballooning can be a stumbling block even for experienced observers. Below, we recount some aspects of the history of histological definitions in NASH and propose specific methods to more objectively identify cellular ballooning in routine biopsy assessments.

Full Text

Disease histopathology constitutes a pillar of modern therapeutic medicine. It also provides the essential foundation for ‘non-invasive’ disease assessments which have become increasingly popular in various liver diseases including (perhaps especially so) the assessment of NASH or ‘non-alcoholic steatohepatitis’. Together with Laboratory analysis and Radiological imaging, the histopathology of a potentially severe condition can tell us what we are up against and whether we need to intervene or not. Ultimately, histopathology defines the significance of a condition: how bad is it? Or… is it not bad at all? Should we undertake therapy or should we step back? This depends on the underlying histopathological diagnosis, the associated prognosis and the balance of risk and benefit of a given intervention. So, where does the histological grounding of NAFLD and NASH stand in 2017 in this regard?

Early studies in this field established the existence of a form of non-alcohol related chronic hepatitis characterized by fatty infiltration of the liver with inflammation, cellular injury evident by inflammation, cellular ballooning and fibrosis.1 The histology was indistinguishable by conventional light microscopy from alcohol-related liver injury.2 The condition could evolve over years to a form of cirrhosis with loss of its primordial histological hallmarks and, in the absence of an antecedent diagnosis, could only be classified as ‘cryptogenic’ cirrhosis.3-5 However, these associations left something of a conundrum between the previously described ‘benign’ fatty liver with no significant long-term sequela6 and another form that worsens to cirrhosis, decompensated liver disease and sometimes to hepatocellular cancer.

Art McCullough, et al. recognized that some forms of nonalcoholic fatty liver disease (NAFLD) were indeed fairly benign over time but others were more clinically significant – so-called ‘Little NASH’ and ‘Big NASH’. They proposed four classes of ‘NAFLD’ - Class 1 and 2: steatosis alone or steatosis with only histological inflammation and classes 3 and 4 which were characterized as having either cellular ballooning or some degree of fibro-sis.7 These latter two groups were subsequently identified as what we know today as NASH. While use of the four histological classes has largely fallen away, this dichotomy of histological findings within the umbrella term ‘NAFLD’ – NASH versus non-NASH fatty liver (or what we refer to as ‘NNFL’) has endured over the years and carries prognostic significance.8,9 It is notable that, although usually considered to be long term stable conditions, transition of NNFL to NASH over time has been reported.10

So where are the problem areas in histological interpretation of NASH or NNFL? Variation in fibrosis staging due to sampling error is well known but can be minimized with core lengths of at least 2 cm.11 Less well known is the existence of variation in the identification of hepatocellular ballooning. Hepatocellular ballooning or ‘balloon degeneration’ in NASH is defined as rounded hepatocyte enlargement > 1.5 – 2 times the normal diameter with loss of the usual polygonal shape of the cell and usually containing pale staining cytoplasm, variably sized cytoplasmic vacuoles, and frequently Mallory Denk bodies. Using specialized stains, it is now known that these cells have significant destruction of the keratin cytoskele-ton (‘keratin empty cells’),12 activated sonic hedgehog sig-naling13 and accumulation of small to medium sized fat droplets with oxidized phospholipids and altered perili-pin expression as well as dilation of the endoplasmic retic-ulum.14 These characteristic cells have also been dubbed the ‘undead’ cells which are a maladapted source of noxious substances that promote their survival but amplify the local injury.15

Although there is little debate when these cells are abundant and markedly enlarged, it can be more challenging when there is a less striking presence on routine H&E staining resulting in a degree of observer dependent sub-jectivity.16 This situation likely explains at least some of the inter-observer variation in NASH biopsy scoring since hepatocellular ballooning accounts for a significant portion of scoring systems like the NAFLD Activity Score (NAS)17,18 and the Steatosis, Activity, and Fibrosis score (SAF).19 This problem can also introduce variability in study results too where balloon scores serve as a target of treatment.20

A degree of uncertainty is inherent in many aspects of Medical Science and it seems to always grow as one parses an issue into ever more granular aspects and thus requires attention to minimize doubt. Distinguishing NASH from non-NASH fatty liver carries significant prognostic and therapeutic implications. Although the histological diagnosis of NASH (present or not present) isn’t dependent on any single parameter,21 detection of ballooning provides a more confident diagnosis. While not widely adopted, we suggest that the incorporation of stains such as keratin or sonic hedgehog into routine liver biopsy processing is warranted to more objectively and consistently identify NASH-related ballooning and more confidently establish the prognosis.

References
[1.]
Ludwig J., Viggiano T.R., McGill D.B., Ott B.J..
Nonalcoholic stea-tohepatitis: Mayo Clinic experiences with a hitherto unnamed disease.
Mayo Clin Proc, 55 (1980), pp. 434-438
[2.]
Diehl A.M., Goodman Z., Ishak K.G..
Alcohol-like liver disease in nonalcoholics.
Gastroenterology, 95 (1988), pp. 1056-1062
[3.]
Powell E.E., Cooksley W.G., Hanson R., Searll J., Halliday J.W., Powell L.W..
The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years.
Hepatology, 11 (1990), pp. 74-80
[4.]
Caldwell S.H., Oelsner D.H., Iezzoni J.C., Hespenheide E.E., Battle E.H., Driscoll C.J..
Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease.
Hepatology, 29 (1999), pp. 664-669
[5.]
Poonawala A., Nair S.P., Thuluvath P.J..
Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study.
Hepatology, 32 (2000), pp. 689-692
[6.]
Teli M.R., James O.F.W., Burt A.D., Bennett M.K., Day C.P..
The natural history of nonalcoholic fatty liver: A followup study.
Hepatology, 22 (1995), pp. 1714-1719
[7.]
Matteoni C.A., Younossi Z.M., Gramlich T., Boparai N., Liu Y.C., McCullough A.J..
Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity.
Gastroenterology, 116 (1999), pp. 1413-1419
[8.]
Ekstedt M., Franzen L.E., Mathiesen U.L., et al.
Long-term follow-up of patients with NAFLD and elevated liver enzymes.
Hepatology, 44 (2006), pp. 865-873
[9.]
Rafiq N., Bai C., Fang Y., et al.
Long-term follow-up of patients with nonalcoholic fatty liver.
Clin Gastroenterol Hepatol, 7 (2009), pp. 234-238
[10.]
McPherson S., Hardy T., Henderson E., Burt A.D., Day C.P., Anstee Q.M..
Evidence of NAFLD progression from steatosis to fibros-ing-steatohepatitis using paired biopsies: implications for prognosis and clinical management.
J Hepatol, 62 (2015), pp. 1148-1155
[11.]
Ratziu V., Charlotte F., Heurtier A., Gombert S., Giral P., Bruck-ert E., Grimaldi A., et al.
LIDO Study Group. Sampling variability of liver biopsy in nonalcoholic fatty liver disease.
Gastroen-terology, 125 (2005), pp. 1898-1906
[12.]
Lackner C., Gogg-Kamerer M., Zatloukal K., Stumptner C., Brunt E.M., Denk H..
Ballooned hepatocytes in steatohepatitis: the value of keratin immunohistochemistry for diagnosis.
J Hepatol, 48 (2008), pp. 821-828
[13.]
Rangwala F., Guy C.D., Lu J., Suzuki A., Burchette J.L., Abdel-malek M.F., Chen W., et al.
Increased production of sonic hedgehog by ballooned hepatocytes.
J Pathol, 224 (2011), pp. 401-410
[14.]
Caldwell S., Ikura Y., Dias D., Isomoto K., Yabu A., Moskaluk C., Pramoonjago P., et al.
Hepatocellular ballooning in NASH.
J Hepatol, 53 (2010), pp. 719-723
[15.]
Hirsova P., Gores G.J..
Ballooned hepatocytes, undead cells, sonic hedgehog, and vitamin E: therapeutic implications for nonalcoholic steatohepatitis.
Hepatology, 61 (2015), pp. 15-17
[16.]
Kleiner D.E., Yah M.M., Guy C.D., Ferrell L., Cummings O., Contos M.J., Brunt E.M., et al.
Creation of a continuous visual scale of ballooned hepatocytes in non-alcoholic fatty liver disease.
Hepatology, 48 (2008), pp. 815A
[17.]
Juluri R., Vuppalanchi R., Olson J., Unalp A., Van Natta M.L., Cummings O.W., Tonascia J., et al.
Generalizability of the Nonalcoholic Steatohepatitis Clinical Research Network histologic scoring system for nonalcoholic fatty liver disease.
J Clin Gastroenterol, 45 (2011), pp. 55-58
[18.]
Gawrieh S., Knoedler D.M., Saeian K., Wallace J.R., Komorowski R.A..
Effects of interventions on intra- and interobserver agreement on interpretation of nonalcoholic fatty liver disease histology.
Ann Diagnost Path, 15 (2011), pp. 19-24
[19.]
Bedossa P., FLIP Pathology Consortium.
Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease.
Hepatology, 60 (2014), pp. 565-575
[20.]
Argo C.K., Ikura Y., Lackner C., Caldwell S.H..
The fat droplet in hepatocellular ballooning and implications for scoring nonalcoholic steatohepatitis therapeutic response.
Hepatology, 63 (2016), pp. 1056-1057
[21.]
Yeh M.M., Brunt E.M..
Pathology of nonalcoholic fatty liver disease.
Am J Clin Pathol, 128 (2007), pp. 837-847
Copyright © 2017. Fundación Clínica Médica Sur, A.C.
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

Quizás le interese:
10.1016/j.aohep.2019.11.007
No mostrar más